Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial Board568
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor295
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma248
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer227
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea212
Editorial Board212
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor208
Unraveling the secrets: Evolution of resistance mediated by membrane proteins202
Erratum to “A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24- enriched breast cancer stem-like cells” [Drug Resist. Updates 66 (2023) 100903]175
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance145
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma143
Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer143
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome142
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer137
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects133
Editorial Board131
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China130
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae126
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions125
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance116
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies110
A novel frameshift mutation in a case of therapy-resistant metastatic pheochromocytoma99
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis98
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer91
Evolution of RND efflux pumps in the development of a successful pathogen88
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges87
Peptide nanonet trapping suppresses bacterial motility and delays antibiotic resistance emergence81
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma80
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC79
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells77
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs76
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation73
IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms71
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs70
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond68
Targeting anoikis resistance as a strategy for cancer therapy68
Editorial Board66
Corrigendum to “RNF26 regulating tumor immunogenicity of hepatocellular carcinoma by degrading GRP78 and instigating ER stress” [Drug Resist. Updat. 86 (2026) 101375]66
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity65
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress65
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer62
The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: Implications for therapy resistance and tumor recurrence62
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica62
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer61
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights61
Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance59
Research progress on gene mutations and drug resistance in leukemia58
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds56
Current therapy and drug resistance in metastatic castration-resistant prostate cancer52
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers52
Myeloid immune checkpoint blockade overcomes antibiotic resistance in bone infection by enhancing efferocytosis and suppressing MSC PANoptosis51
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma51
Emergence of novel Klebsiella pneumoniae ST types with multidrug resistance in clinic51
Overcoming cancer chemotherapy resistance by the induction of ferroptosis51
0.3935399055481